We, Implementer constituencies, would like to express serious concerns with regard to the implications of the combined financial and operational information shared with us ahead of the 33rd Meeting of the Global Fund Board, specifically:
- The TRP and SIIC stated in their reports that there is a trend of flat lining ART scale-up within the context of resource constraints and major gaps in the coverage of continuity of ART services;
- TB programs continues to be underfunded, and more so for MDR TB treatment, at the same time as the TB disease burden is being re-evaluated upwards;
- There remain significant gaps in funding for continuity of essential services for malaria (especially vector control) during 2016-2017, which are endangering the gains already achieved, while scale-up for impact is urgently required, particularly in the context of emerging drug and insecticide resistance;
- Unfunded quality demand (UQD) in the amount of $2 billion has already been registered, with more to be expected.
Yet, at the same time as inadequate resources are constraining scale-up:
- The Secretariat is reporting far slower grant expense rates (-25% in 2014, B33/02, slide 5).
- Disbursements have decreased from 3,946 billion in 2013 to 2,895 billion in 2014 (B33/03, page 14)
Our concern is that a significant portion of the Global Fund’s current allocated resources are unlikely to be used optimally and in a timely manner in this replenishment period.
This is unnecessary and demonstrates a lack of urgency in the drive towards impact in the face of significant unfunded quality demand and actual funding gaps that are preventing the Global Fund from addressing real people’s urgent health needs and delivering on its mission.
We therefore call on the Board to urgently discuss and address these critical issues. We would welcome options being presented at the next Board Committee meetings on how to address the flat lining of scale-up activities and a more optimal use of Global Fund finances.